Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label BGJ398 in recurrent FGFR-altered glioblastoma
NL-OMON44518Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of infigratinib in glioblastoma (GBM) and glioma (2 cohorts), sponsored by Novartis. Primary endpoint: Progression-free survival rate at 6 months. Started Aug 2014; status: active, not recruiting.
02
Drugs
infigratinib
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NL-OMON44518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44518.